161 related articles for article (PubMed ID: 38597415)
41. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
42. Microenvironment Analysis of Prognosis and Molecular Signature of Immune-Related Genes in Lung Adenocarcinoma.
Ling B; Huang Z; Huang S; Qian L; Li G; Tang Q
Oncol Res; 2021 Mar; 28(6):561-578. PubMed ID: 32471520
[TBL] [Abstract][Full Text] [Related]
43. A novel zinc metabolism-related gene signature to predict prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Ou W; Wang SY
Front Immunol; 2023; 14():1147528. PubMed ID: 37033934
[TBL] [Abstract][Full Text] [Related]
44. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
45. Development and Validation of a Machine Learning Prognostic Model of m5C Related immune Genes in Lung Adenocarcinoma.
Cao X; Ji Y; Li J; Liu Z; Chen C
Cancer Control; 2024; 31():10732748241237414. PubMed ID: 38537151
[TBL] [Abstract][Full Text] [Related]
46. Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma.
Zhang P; Pei S; Wu L; Xia Z; Wang Q; Huang X; Li Z; Xie J; Du M; Lin H
Front Endocrinol (Lausanne); 2023; 14():1196372. PubMed ID: 37265698
[TBL] [Abstract][Full Text] [Related]
47. Integrated multi-omics analysis and machine learning to refine molecular subtypes, prognosis, and immunotherapy in lung adenocarcinoma.
Han T; Bai Y; Liu Y; Dong Y; Liang C; Gao L; Zhou J; Guo J; Wu J; Hu D
Funct Integr Genomics; 2024 Jun; 24(4):118. PubMed ID: 38935217
[TBL] [Abstract][Full Text] [Related]
48. Glycolysis induces Th2 cell infiltration and significantly affects prognosis and immunotherapy response to lung adenocarcinoma.
Zeng L; Liang L; Fang X; Xiang S; Dai C; Zheng T; Li T; Feng Z
Funct Integr Genomics; 2023 Jul; 23(3):221. PubMed ID: 37400733
[TBL] [Abstract][Full Text] [Related]
49. A single-cell characterised signature integrating heterogeneity and microenvironment of lung adenocarcinoma for prognostic stratification.
Xu J; Zhang Y; Li M; Shao Z; Dong Y; Li Q; Bai H; Duan J; Zhong J; Wan R; Bai J; Yi X; Tang F; Wang J; Wang Z
EBioMedicine; 2024 Apr; 102():105092. PubMed ID: 38547579
[TBL] [Abstract][Full Text] [Related]
50. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
52. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
53. Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.
Zhang S; Li M; Tan Y; Zhang J; Liu Y; Jiang W; Li X; Qi H; Tang L; Ji R; Zhao W; Gu Y; Qi L
J Mol Med (Berl); 2022 Dec; 100(12):1755-1769. PubMed ID: 36367565
[TBL] [Abstract][Full Text] [Related]
54. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
55. An artificial intelligence network-guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms.
Zhang N; Zhang H; Liu Z; Dai Z; Wu W; Zhou R; Li S; Wang Z; Liang X; Wen J; Zhang X; Zhang B; Ouyang S; Zhang J; Luo P; Li X; Cheng Q
Cell Prolif; 2023 Apr; 56(4):e13409. PubMed ID: 36822595
[TBL] [Abstract][Full Text] [Related]
56. Characterization of the immune cell infiltration landscape in lung adenocarcinoma.
Ou HB; Wei Y; Liu Y; Zhou FX; Zhou YF
Arch Biochem Biophys; 2022 May; 721():109168. PubMed ID: 35346643
[TBL] [Abstract][Full Text] [Related]
57. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
Yang Q; Zhu W; Gong H
Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
[TBL] [Abstract][Full Text] [Related]
58. Identification of an Amino Acid Metabolism-Related Gene Signature for Predicting Prognosis in Lung Adenocarcinoma.
Chang W; Li H; Wu C; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553562
[TBL] [Abstract][Full Text] [Related]
59. Single-cell and Bulk RNA-Seq reveal angiogenic heterogeneity and microenvironmental features to evaluate prognosis and therapeutic response in lung adenocarcinoma.
Tang L; Chen Z; Yang J; Li Q; Wang S; Mo T; Zeng W; Ding H; Pan S
Front Immunol; 2024; 15():1352893. PubMed ID: 38390340
[TBL] [Abstract][Full Text] [Related]
60. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
